Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT101 in Type 1 Diabetes
NCT05428943Phase 1Completed
- Sponsor
- Op-T
- Start
- Sep 2022
- Primary completion
- Feb 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OPT101 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Op-T. Primary endpoint: Treatment-related Adverse Events at 42 days. Started Sep 2022; status: completed.
02
Drugs
OPT101
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05428943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05428943.